First quarter earnings reports from Johnson & Johnson and Abbott Laboratories provided some surprising insights into the ...

Johnson & Johnson’s Medtech division reported the completion of the first cases in the clinical trial for the Ottava robotic ...

After more than three years of discussion, the World Health Organization’s Intergovernmental Negotiating Body (INB) has ...

Genes associated with lysosomal dysfunction increase the risk of Parkinson’s disease (PD), according to a study led by ...

Nipah virus, which circulates in fruit bats and other animals primarily in Asia and the South Pacific, causes severe ...

China’s National Medical Products Administration (NMPA) has accepted Innocare Pharma Ltd.’s NDA for its second-generation pan-tropomyosin receptor kinase inhibitor, zurletrectinib (ICP-723), for ...

Eli Lilly and Co. aired positive top-line data from the phase III trial called Achieve-1 testing orforglipron vs. placebo in adults with type 2 diabetes and inadequate glycemic control with diet and ...

The recent staff cuts at the U.S. FDA’s device center caught the attention of outsiders but also caught the attention of those who work on premarket applications for 510(k) and PMA filings.

Researchers have developed a new compound that can prevent long COVID symptoms in mice that could lead to a future drug for ...

Dravet syndrome (DS) is a rare and severe form of epilepsy that causes intellectual disability and motor deficits and can lead to premature death. A loss-of-function mutation in one copy of SCN1A, ...

The University of Michigan has divulged lysine-specific histone demethylase 1A (KDM1A; LSD1) inhibitors reported to be useful for the treatment of cancer, autism, myocardial fibrosis and more.

BHV-8000 from Biohaven Pharmaceuticals Inc. is a dual, brain-penetrant, oral small molecule that is highly selective against TYK2 and JAK1 enzymes, which are essential enzymes to the inflammatory ...